Document is current

Any future updates will be listed below

2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)

Crossref DOI link: https://doi.org/10.1007/s12467-013-0037-3

Published Online: 2015-03-18

Published Print: 2013-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark